Proteomics has undergone a revolution and circulating protein biomarkers are increasingly used in multiomics studies and to accelerate drug development. Olink’s unique Proximity Extension Assay (PEA) technology enables high-throughput protein analyses and offers reliable detection of over 5300 proteins from just 2 µL of sample. The platform's scalability allows for a broad range of multiplexing levels across various therapeutic areas, with panels covering all major biological processes and key diseases, including cancer, inflammation, and aging-related disorders. In this scientific seminar we will discuss the capabilities of PEA and present case studies highlighting the importance of proteomics in the multiomics world. Proteins are the dynamic indicators of phenotype in health and disease, and we will show how protein biomarkers are key to reveal true biological insights and accelerate our understanding of complex diseases. The deep understanding of real-time biology provided by proteomic data will help with faster drug discovery and accelerate the development of successful new therapies, facilitating the move towards precision medicine approaches and individualized healthcare.